Search Result

Results for "

subclass

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD20 (1) HBV (1) Wnt (2)
By Research Areas:	Cancer (5) Infection (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1454

Fz7-21 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-P1454A

Fz7-21 TFA 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2 TFA	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .

HY-P992095

Nofetumomab	CD20	Cancer
Nofetumomab is an anti-human monoclonal antibody targeting CD20. Nofetumomab can be used for the research cancer .

Cat. No.	Product Name	Target	Research Area

HY-P1454

Fz7-21 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .

HY-P1454A

Fz7-21 TFA 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2 TFA	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990679

Rat IgG2a kappa, Isotype Control 3 Publications Verification	Inhibitory Antibodies	Inflammation/Immunology Cancer
Rat IgG2a kappa, Isotype Control is a monoclonal antibody derived from rats, representing the immunoglobulin G2a (IgG2a) subclass with a kappa light chain. Rat IgG2a kappa, Isotype Control exhibits high efficiency in inducing K cell mediated cytotoxicity. Rat IgG2a kappa, Isotype Control is utilized in research investigating the roles of different immunoglobulin subclasses in tumor immunology. Rat IgG2a kappa, an isotype control, can be used as an isotype control for Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144), Anti-Mouse CD11a/LFA-1α Antibody (M17/4) (HY-P990801), and Anti-Mouse IL-2 Antibody (S4B6-1) (HY-P990796) .

HY-P99541

Tuvirumab anti-hepatitis B; OST 577; SDZ-OST 577	HBV	Infection
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .

HY-P991230

MK-4830	Inhibitory Antibodies	Cancer
MK-4830 is a fully humanized monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .

HY-P992095

Nofetumomab	CD20	Cancer
Nofetumomab is an anti-human monoclonal antibody targeting CD20. Nofetumomab can be used for the research cancer .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86845

	DCC Antibody (YA6538) Colorectal cancer related chromosome sequence 18 antibody; Colorectal cancer suppressor antibody; CRC 18 antibody; CRC18 antibody; CRCR 1 antibody; CRCR1 antibody; DCC antibody; DCC_HUMAN antibody; Deleted in colorectal cancer protein antibody; Deleted in colorectal carcinoma antibody; Colorectal cancer related chromosome sequence 18 antibody; Colorectal cancer suppressor antibody; CRC 18 antibody; CRC18 antibody; CRCR 1 antibody; CRCR1 antibody; DCC antibody; DCC_HUMAN antibody; Deleted in colorectal cancer protein antibody; Deleted in colorectal carcinoma antibody; Immunoglobulin superfamily DCC subclass member 1 antibody; Netrin receptor DCC antibody; Tumor suppressor protein DCC antibody;	WB, IHC-F	Human, Mouse, Rat
	DCC Antibody (YA6538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DCC.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.